Founded in 1960, Cipan is a company committed to health, and this has been demonstrated in its more than 50-year history Cipan has developed, either through its own investment or through CDO strategies, three generations of APIs derived from Tetracycline: Tetracycline, Minocycline, Lymecycline, Oxytetracycline, and other third-generation molecules that are currently in commercial phase (CMO) or development (CDO). Cipan is one of the top 3 companies in producing APIs through fermentation processes, or chemical synthesis processes, which makes it very versatile and the right partner to understand the needs of any client. Its wide international presence gives Cipan the proven ability to manufacture according to the most demanding standards required by top-level agencies such as the EMA, FDA or CFDA. In addition, Cipan has its own Registry department which combines knowledge of the entire value chain of the life cycle of a medicine, from its development to the preparation of the regulatory dossier for its commercialization.